SCM
ALNY icon

SCS Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

SCS Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.8M Sell
115,549
-33,998
-23% -$10.3M 0.33% 47
2026
Q1 		$49.5M Sell
149,547
-64
-0% -$21.8K 0.52% 32
2025
Q4 		$59.5M Sell
149,611
-1,057
-0.7% -$468K 0.63% 25
2025
Q3 		$68.7M Sell
150,668
-19,994
-12% -$8.14M 0.75% 21
2025
Q2 		$55.7M Sell
170,662
-415
-0.2% -$115K 0.62% 25
2025
Q1 		$46.2M Buy
+171,077
New +$44M 0.59% 28

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCS Capital Management's ALNY Position: Q2 2026 in Review

SCS Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 23% in Q2 2026, selling an estimated $10.3M and leaving 115,549 shares worth $34.8M. The position accounts for 0.33% of the portfolio, ranked #47.

SCS Capital Management first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. The position peaked at $68.7M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • SCS Capital Management held 115,549 shares of Alnylam Pharmaceuticals worth $34.8M as of Q2 2026.
  • SCS Capital Management sold 33,998 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $10.3M.
  • Alnylam Pharmaceuticals made up 0.33% of SCS Capital Management's portfolio in Q2 2026, its #47 holding.
  • SCS Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • SCS Capital Management's Alnylam Pharmaceuticals position peaked at $68.7M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.